一个可吸入的纳米粒子,可以消除毒性因子,并为肺炎球菌肺炎治疗提供抗生素
Huiyue Dong1, Yuxin Zhao1, Shihong Li2
1School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
概括
一种新的可吸入纳米组件可以提供抗生素并中和过氧化,用于治疗Streptococcus pneumoniae肺炎. 这种双重作用的方法提高了治疗效率,并提高了肺炎模型中的存活率.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 传染性疾病 传染性疾病
背景情况:
- 肺炎链球菌会导致社区获得的肺炎.
- 提供抗生素和过氧化是肺炎治疗的关键挑战.
- 目前的治疗方法在有效打击S. pneumoniae方面存在局限性.
研究的目的:
- 开发一种可吸入的纳米组件,用于向药物输送和毒性因子中和.
- 为了研究催化剂-酸纳米组合与勒沃素对肺炎球菌肺炎的治疗潜力.
- 为了克服常规抗生素治疗肺炎的局限性.
主要方法:
- 一种可吸入的催化酶 (CAT) - - 酸 (TA) 纳米组件的配方,载有levfloxacin (CT@LVX).
- 在肺组织中评估CT@LVX粘结和积累.
- 评估CAT在中和过氧化和减少亡方面的有效性.
- 在Streptococcus pneumoniae肺炎小鼠模型中的体内测试.
主要成果:
- CT@LVX证明了有效的粘膜凝聚和肺积累.
- catalase活性通过分解H2O2.2,减少了膜上皮细胞的亡.
- 结合抗生素和H2O2中和导致肺损伤和炎症的减少.
- 在肺炎诱导的小鼠中实现了100%的生存率.
结论:
- CT@LVX纳米组件为治疗肺炎球菌性肺炎提供了一个有前途的双重作用策略.
- 这种方法有效地在局部提供抗生素,并中和细菌毒性因素.
- 与传统抗生素治疗相比,CT@LVX显示出更优异的治疗结果,这表明了临床潜力.
更多相关视频
07:28Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
40.6K
07:43A Non-invasive and Technically Non-intensive Method for Induction and Phenotyping of Experimental Bacterial Pneumonia in Mice
Published on: September 28, 2016
9.0K
相关概念视频
01:23Inhaled Medications
240
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
240
01:28Pneumonia IV: Management
308
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
308